Determinants of Thoracic Electrical Impedance in External Electrical Cardioversion of Atrial Fibrillation - 17/08/11
, Nadia Boni, MD a, Margherita Padeletti, MD a, Francesca Gori, MD a, Lorenzo Boncinelli, MD a, Paolo Valoti, MD a, Samuele Baldasseroni, MD a, Mauro Di Bari, MD, PhD a, Giulio Masotti, MD a, Luigi Padeletti, MD b, Serge Barold, MD c, Niccolò Marchionni, MD aRésumé |
The success of external cardioversion (ECV) of atrial fibrillation depends on generating sufficient transmyocardial current for defibrillation with minimal myocardial injury. Thoracic electrical impedance plays an important role in the relation between the delivered energy and transmyocardial current. This study assessed the determinants of thoracic electrical impedance in ECV of atrial fibrillation. ECV of atrial fibrillation was performed in 80 consecutive patients (mean age 73 ± 9 years; men 69%; body mass index 26.0 ± 3.6 kg/m2) within 12 months, using biphasic shocks (Multipulse Biowave) delivered through adhesive pads in an anteroposterior position. Thoracic electrical impedance was measured using the first shock. The mean thoracic electrical impedance was 57.7 ± 12.3 Ω (energy 71 ± 43 J, current intensity 33 ± 12 A). Sinus rhythm was immediately restored in 75 patients (94%). Thoracic electrical impedance was greater (60.9 ± 11.8 vs 51.7 ± 11.0 Ω, p = 0.001) in patients requiring >1 shock (65%). At multivariate linear regression analysis (R = 0.761, p <0.001), female gender (+9.7 ± 2.0 Ω, p <0.001), body mass index (+1.5
± 0.3 for a 1 kg/m2 increase, p <0.001), hemoglobin concentration (+1.9 ± 0.6 for a 1 g/dl increase, p = 0.004), and the presence of chronic heart failure (−5.3 ± 2.0 Ω, p = 0.009) were independent predictors of thoracic electrical impedance. In conclusion, to increase ECV efficacy and minimize complications, the delivered energy should be adjusted in accordance with the clinical variables that independently affect thoracic electrical impedance and, hence, transmyocardial current.
Plan
| Technical support for this study was supplied by ESAOTE SpA, Florence, Italy, and Schiller Medical AG, Switzerland, which supplied the defibrillator and paddles used to perform electrical cardioversion. Neither company had any role in the study design or conduction, data management, analysis, interpretation, or writing of this report. None of the investigators received any personal or research support other than that mentioned nor has any personal involvement in either company. |
Vol 98 - N° 1
P. 82-87 - juillet 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
